Ibrutinib Synthesis via Copper-Catalyzed Coupling and Stereocontrol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing Btk inhibitors are inefficient and lack specificity, which hampers the development of effective therapies targeting Bruton's tyrosine kinase (Btk) in hematopoietic cells.
Innovation Solution
A process for synthesizing the Btk inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib) is described, involving the reaction of specific compounds in the presence of catalysts like copper salts and bases, optimizing yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional synthesis methods are used for Btk inhibitors, then the production process is simple, but the efficiency is low and specificity is poor
Solution Approach 1:
The synthesis process is divided into multiple discrete steps: (1) forming the pyrazolo-pyrimidine core, (2) introducing the piperidine ring, (3) adding the prop-2-en-1-one side chain, and (4) stereochemical control at the R-configuration center. Each step uses specific reagents and conditions to build complexity incrementally while maintaining efficiency.
Solution Approach 2:
The patent employs preliminary actions by using protected intermediates and pre-formed building blocks. For example, the pyrazolo-pyrimidine core is synthesized first as a stable intermediate, then used in subsequent coupling reactions. This avoids repeated synthesis of the same core structure and improves overall efficiency.
2Manufacturing precision
If conventional synthesis methods are used, then the production process is straightforward, but the yield and purity are insufficient
Solution Approach 1:
The patent extracts and removes impurities at specific stages through purification steps. After each major transformation, the mixture is processed to separate the desired product from byproducts. This targeted extraction approach maintains high purity without requiring overly complex continuous purification systems.
Solution Approach 2:
The synthesis utilizes parameter changes in reaction conditions to control purity. Specific temperature ranges, pH levels, and reagent ratios are optimized at each step to favor the desired product. For example, stereochemical purity is controlled by adjusting reaction conditions to favor formation of the R-configuration while minimizing racemization.
3Reliability
If conventional synthesis methods are used, then the process is easy to implement, but the therapeutic effectiveness is limited
Solution Approach 1:
The patent introduces asymmetry through stereochemical control at the R-configuration center in the piperidine ring. This chiral center is created using asymmetric synthesis methods that favor formation of the R-enantiomer, which is the biologically active form for Btk inhibition. This asymmetric approach improves therapeutic effectiveness by ensuring the correct stereochemistry.
Solution Approach 2:
The patent uses intermediary compounds that serve as bridges between starting materials and the final product. These intermediaries are designed to facilitate specific transformations while maintaining high fidelity to the target structure. The intermediaries enable precise control over the final molecule's properties, improving therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This synthetic process enhances the efficiency and specificity of ibrutinib production, leading to a more effective Btk inhibitor with improved therapeutic potential for hematological disorders.
Implementation Method 1
the reacting the compound of Formula (II) with a compound of Formula (III) is in the presence of a catalyst, such as a copper salt
Implementation Method 2
In some embodiments, the base is an inorganic base, such as MOH, M2CO3 (wherein M is selected from lithium, sodium, potassium, and cesium), CaCO3, di- and tri-basic phosphates (e.g. M3PO4, M2HPO4) or bicarbonates (MHCO3)
Data Source
AI summary
Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.